Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
60.06 ^USD	-0.40%		-0.92%	-4.36%

Apr. 25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT
Apr. 22	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	Apr. 25
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	Apr. 22
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	Mar. 21
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	Mar. 04
Vaxcyte Q4 Loss Widens	Feb. 27
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	Feb. 02
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	Jan. 31
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	Jan. 31
Vaxcyte Launches Securities Offering; Shares Fall After Hours	Jan. 30
Sector Update: Health Care Stocks Advance Monday Afternoon	Jan. 29
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate	Jan. 29
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate	Jan. 29
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	Jan. 29
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing	Jan. 25
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing	Jan. 19
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer	Jan. 16
Vaxcyte Shares Drop After Clinical Pipeline Updates	Jan. 05
Vaxcyte Insider Sold Shares Worth $828,915, According to a Recent SEC Filing	Jan. 04
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise	Jan. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Other languages

Filters